Clinical Data — Investor Presentation (May 2008)
30 slides from Clinical Data's investor presentation, May 8, 2008
Slide 1: Investor Presentation
1 Investor Presentation Drew Fromkin, President and Chief Executive Officer, Director
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private
Slide 3: Corporate Snapshot
3 Corporate Snapshot Headquarters Newton, MA NASDAQ CLDA 52 Week Price Range $13.00 to $28.90 Shares Outstanding 20.9 MM Cash (12/31/07) $77 MM
Slide 4: Mission
4 Mission To develop and commercialize predictive tests and targeted therapeutics from our growing portfolio of proprietary biomarkers of drug response
Slide 5: Company Highlights
5 Company Highlights Emerging pharmacogenomics pure play Proprietary diagnostics and therapeutics High margins, large markets Regulated and unregulated genomics services Late stage drug candidate Released positive results from Phase III study of Vilazodone, the Company's candidate drug for depressio
Slide 6: CLDA Businesses
6 CLDA Businesses Proprietary Pharmacogenetic Tests Comprehensive Genomics Services Targeted Therapeutics Mainstream Clinical Care Patients Providers Payers Clinical Trials and Research Biotech/ Pharmaceutical Companies
Slide 7: Expertise and Proprietary Genetic Markers of Drug Response
7 Expertise and Proprietary Genetic Markers of Drug Response PGxHealth Targeted drugs launched with companion pharmacogenetic tests Companion tests launched as companion or combination product Pharmacogenetic tests launched independently of associated drug Foundation Intellectual Property Developing
Slide 8: PGx Tests and Drugs: Value Proposition
PGx Tests and Drugs: Value Proposition Pharma PGxDrugs Generic Labs PGxTests Large Large Low Low Large Large Large Large Large Large Huge Moderate Moderate Small Small Large Moderate Small Small Small Yes Yes No No Yes Slowing Increasing Steady Mature Rapid Margin Volume R&D Costs Development Risks
Slide 9: Genetic Biomarker Intellectual Property
9 Genetic Biomarker Intellectual Property Difficult to Diagnose Diseases or Syndromes Familial Long QT Syndrome Brugada Syndrome Related familial arrhythmogenic disorders Drug Receptors FCGAMMA IIIA (monoclonal antibodies) VKORC1 (warfarin) ADME Genes Transport MDR1, OCT1, MRP1 Metabolism CYP 2B6 CY
Slide 10: Targeted Therapeutic: Vilazodone
Targeted Therapeutic: Vilazodone
Slide 11: Targeted Therapeutic: Vilazodone
11 Targeted Therapeutic: Vilazodone Profile: Genetically guided dual serotonergic in development for the treatment of depression Dual mechanism of action (SSRI and 5HT1A partial agonist) Worldwide exclusive license to Vilazodone patent estate from Merck KGaA (now Merck-Serono) Biomarker intellectual
Slide 12: Vilazodone Phase III Study
Vilazodone Phase III Study Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder (MDD) 8 week, single dose trial Randomized, double-blind placebo controlle
Slide 13: Vilazodone Phase III Study Design
Vilazodone Phase III Study Design Patients 18-65 years of age with a diagnosis of MDD according to DSM-IV-TR Disease severity assessed by Score on HAM-D17 HAM-D item 1 (depressed mood) score ^ 2 Minimum baseline score of ^ 22 on HAMD17 Week 0 10 mg Week 1 20 mg Week 2 40 mg Week 8 End of Study
Slide 14: Statistical Significance on Primary and Secondary Efficacy Endpoints
Statistical Significance on Primary and Secondary Efficacy Endpoints Secondary Efficacy Endpoints Secondary Efficacy Endpoints amean +-SD bmean +-SE *least square mean comparison with ANCOVA Table 1. Mean change from baseline at Week 8 (ITT, LOCF)
Slide 15: Separation Between Vilazodone and Placebo Occurs Early in Treatment
Separation Between Vilazodone and Placebo Occurs Early in Treatment - - ITT, LOCF - - P-values are for comparisons of vilazodone and placebo by ANCOVA Least squares mean change from baseline for MADRS
Slide 16: Vilazodone Appears to be Well Tolerated Over Weeks of Treatment
Vilazodone Appears to be Well Tolerated Over 8 Weeks of Treatment Number (%) of Patients Number (%) of Patients Number (%) of Patients Number (%) of Patients Number (%) of Patients Number (%) of Patients Vilazodone N=205 Vilazodone N=205 Vilazodone N=205 Placebo N=204 Placebo N=204 Placebo N=204 Adv
Slide 17: A Biomarker Identifies 30% of Patients with Significantly More Improvement
A Biomarker Identifies 30% of the Patients with Significantly More Improvement After 8 Weeks of Treatment with Vilazodone Vilazodone Vilazodone Placebo Placebo M+ M- M+ M- Na 49 108 39 128 LS-Mean (SE) -19.3 (1.59) -12.4 (1.26) -13.0 (1.86) -11.8 (1.18) 95% CI (LS-Mean) (-22.4, -16.2) (-14.9, -10.0)
Slide 18: A Biomarker Identifies 30% of Patients with Significantly More Improvement
A Biomarker Identifies 30% of the Patients with Significantly More Improvement After 8 Weeks of Treatment Least square means of observed MADRS total score by week for Biomarker
Slide 19: Vilazodone Development Plan: Milestones
19 Vilazodone Development Plan: Milestones Second Phase III study of efficacy launched March 2008 Pre-specified analysis of biomarkers Study expected to be completed year-end 2008 Long-term safety study launched December 2007 Will close enrollment 6 weeks ahead of schedule Manufacture of commercial
Slide 20: PGxHealth: Predictive Tests
PGx:HEALTH" © A DIVISION OF CLINICAL DATA Predictive Tests cuinicaug para
Slide 21: Genetic Testing Landscape
21 Genetic Testing Landscape Direct-to-consumer Risk for disease Difficult to diagnose diseases with links to treatment Pharmacogenetic tests for drug prescription Examples Marketed by Whole Genome Scans Paternity Vitamins Disease Markers Prostate Cancer Parkinson's Disease Alzheimer's Disease Valua
Slide 22: PGxPredict Tests
22 PGxPredictTM Tests Improve treatment approach Reduce costs associated with trial and error prescribing Enhance patients' response to drugs early in treatment Reduce side effects
Slide 23: Currently Offered Pharmacogenetic Tests
(1) Prevalence & incidence rates exclude International markets. Sources: Selected industry and academic publications and resources. Test Long Q/T Cardiology ~100,000 (U.S.) 1/3,000 Disease Incidence/ Prevalence Disease/Therapeutic Area ~2,000,000 (U.S.) Annually Coumadin Rx/Warfarin Cardiology Folli
Slide 24: Pharmacogenetic Tests: Pipeline
24 Cardiovascular CNS Oncology Inflammatory Diseases Pharmacogenetic Tests: Pipeline
Slide 25: Payer Progress
Progress since last update on February 28th Now an approved Medicaid provider in 28 states covering 25.3 MM lives, up from 13 states and 9 MM lives. Growing number of BCBS plans developing positive coverage, policies as a result of the positive TEC evaluation and individual plan test review. Approxi
Slide 26: The Genomics Services Company
The Genomics Services Company(tm)
Slide 27: Overview
27 Overview High-quality sequencing, gene expression, genotyping and other molecular services worldwide Comprehensive range of services Full range of regulatory compliance Broad customer base, US and international Pharmaceutical, biotech, agricultural, government, academia 19 of top 20 pharmaceutica
Slide 28: Broadest genomics services menu in the industry
28 Broadest genomics services menu in the industry: Sequencing ABI 3730 Roche 454 GS FLX (new) Genotyping RFLP Mapping Sequenom Luminex Illumina iScanTM System Agilent Microarray aCGH miRNA Affymetrix Microarray Whole Genome Association DNA Analysis DME-T Algynomics Pain Chip Gene Expression Analysi
Slide 29: Third Quarter FY 2008 Summary
29 Third Quarter FY 2008 Summary Announced on February 14, 2007 Accomplishments reflect the fundamental value and broad applications of CLDA's expertise and intellectual property as well as its emergence as a pure play genomics company Total revenues from continuing operations: $10.5 MM, up 31% from
Slide 30: Fiscal Year 2009 Objectives
30 Fiscal Year 2009 Objectives Advance Vilazodone development program with target NDA filing of 2009 Drive adoption of proprietary pharmacogenetic tests Leverage new provider sales force Continue payer coverage progress Continue to acquire and develop proprietary genetic markers of drug response to